216 related articles for article (PubMed ID: 17143830)
1. Viral load testing in resource-limited settings.
Schooley RT
Clin Infect Dis; 2007 Jan; 44(1):139-40. PubMed ID: 17143830
[No Abstract] [Full Text] [Related]
2. HIV viral load monitoring in resource-limited regions: optional or necessary?
Calmy A; Ford N; Hirschel B; Reynolds SJ; Lynen L; Goemaere E; Garcia de la Vega F; Perrin L; Rodriguez W
Clin Infect Dis; 2007 Jan; 44(1):128-34. PubMed ID: 17143828
[TBL] [Abstract][Full Text] [Related]
3. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
Bagchi S; Kempf MC; Westfall AO; Maherya A; Willig J; Saag MS
Clin Infect Dis; 2007 Jan; 44(1):135-8. PubMed ID: 17143829
[TBL] [Abstract][Full Text] [Related]
4. Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings.
Lynen L; Van Griensven J; Elliott J
Curr Opin HIV AIDS; 2010 Jan; 5(1):1-5. PubMed ID: 20046141
[TBL] [Abstract][Full Text] [Related]
5. The measurement of HIV-1 viral load in resource-limited settings: how and where?
Rouet F; Rouzioux C
Clin Lab; 2007; 53(3-4):135-48. PubMed ID: 17447649
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 load quantitation: a 17-year perspective.
Holodniy M
J Infect Dis; 2006 Sep; 194 Suppl 1():S38-44. PubMed ID: 16921471
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
8. Monitoring HIV treatment in resource-limited settings: reassuring news on the usefulness of CD4(+) cell counts.
Fowler MG; Owor M
J Infect Dis; 2009 May; 199(9):1255-7. PubMed ID: 19317627
[No Abstract] [Full Text] [Related]
9. HIV-1 viral load testing cost in developing countries: what's new?
Rouet F; Rouzioux C
Expert Rev Mol Diagn; 2007 Nov; 7(6):703-7. PubMed ID: 18020900
[No Abstract] [Full Text] [Related]
10. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings.
Johannessen A; Trøseid M; Calmy A
J Antimicrob Chemother; 2009 Dec; 64(6):1126-9. PubMed ID: 19776036
[TBL] [Abstract][Full Text] [Related]
11. Viral load and combination therapy for human immunodeficiency virus.
Srinivasan V; Beidas SO
N Engl J Med; 1997 Mar; 336(13):960; author reply 961. PubMed ID: 9072699
[No Abstract] [Full Text] [Related]
12. An unjustifiably alarming report of a fatal case of retroviral rebound syndrome.
Angel-Moreno A; Perez-Arellano JL
Clin Infect Dis; 2006 Mar; 42(5):732-3; author reply 733. PubMed ID: 16447127
[No Abstract] [Full Text] [Related]
13. HIV-1 viral dynamics and viral load measurement: implications for therapy.
Riddler SA; Mellors JW
AIDS Clin Rev; 1997-1998; ():47-65. PubMed ID: 9305443
[No Abstract] [Full Text] [Related]
14. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients?
Hill A; Miralles D; Vangeneugden T; Lefebvre E
AIDS; 2007 Jul; 21(12):1651-3. PubMed ID: 17630565
[TBL] [Abstract][Full Text] [Related]
15. Failure of HIV-2 viral load assay in a severely immunodeficient patient: clinical and therapeutic management issues.
Fonquernie L; Eholié SP; Damond F; Lacombe K; Girard PM
Trans R Soc Trop Med Hyg; 2006 Mar; 100(3):282-4. PubMed ID: 16293278
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two commercially available alternatives for HIV-1 viral load testing in resource-limited settings.
Steegen K; Luchters S; De Cabooter N; Reynaerts J; Mandaliya K; Plum J; Jaoko W; Verhofstede C; Temmerman M
J Virol Methods; 2007 Dec; 146(1-2):178-87. PubMed ID: 17686534
[TBL] [Abstract][Full Text] [Related]
17. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania.
Johannessen A; Garrido C; Zahonero N; Sandvik L; Naman E; Kivuyo SL; Kasubi MJ; Gundersen SG; Bruun JN; de Mendoza C
Clin Infect Dis; 2009 Sep; 49(6):976-81. PubMed ID: 19663598
[TBL] [Abstract][Full Text] [Related]
18. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
Hill A; Sabin C
AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
[No Abstract] [Full Text] [Related]
19. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
20. HIV eradication: thinking the unthinkable.
Fox CH; Cottler-Fox M
J Hum Virol; 1999; 2(6):321-4. PubMed ID: 10774548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
